Pipeline
Our investigational repair-enhancing medicines work differently…
Whilst modern medicines are effective in reducing symptoms and slowing decline in chronic disease, they do not prevent their onset, nor do they support the body’s natural repair processes. As a result, patients ‘live with’ chronic diseases, experiencing continued, albeit slower, disease progression, re-emerging symptoms and reduced quality of life compared with healthy individuals.
By modulating the mitochondria – the beating heart of the body’s cells, responsible for energy production and central to everyday cell function, our compounds tune different metabolic and signalling pathways to change how cells behave and function, and promote the body’s natural capacity to repair.
Our investigational medicines offer the potential to go beyond conventional symptom control, to directly prevent or even reverse decline in a broad range of degenerative, autoimmune or fibrotic conditions where tissue damage occurs.
Leramistat is an investigational first-in-class, once-daily pill that works in an exciting new way. With strong promising results in bone and joint damage repair, improvement in disability and fatigue responses and reductions in markers of parainflammation and mitochondrial adaptation, without suppressing the immune system. A notable departure from current approaches, leramistat works by augmenting the body’s inherent repair response to repair and restore damaged tissue as well as build resilience to cycles of further destruction.
Leramistat’s unique mode of action enables the prevention of damage whilst mobilising capacity to repair to restore the cross-talk between muscle and bone, offering potential as a novel treatment for primary sarcopenia of ageing.
Leramistat’s unique mode of action also supports adaptive repair in scarred lung tissue caused by idiopathic pulmonary fibrosis (IPF).
Leramistat has been granted both FDA Fast Track and Orphan Drug Designation (ODD) to support its development and expedite its review to fulfil an unmet medical need in IPF. You can access our expanded access policy here.
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum.
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum.